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Human somatic angiotensin I-converting enzyme (ACE), a zinc-dependent
dipeptidyl carboxypeptidase, is central to the regulation of the renin–angio-
tensin aldosterone system. It is a well-known target for combating hyper-
tension and related cardiovascular diseases. In a recent study by Bhuyan
and Mugesh [Org. Biomol. Chem. (2011) 9, 1356–1365], it was shown that
the selenium analogues of captopril (a well-known clinical inhibitor of
ACE) not only inhibit ACE, but also protect against peroxynitrite-medi-
ated nitration of peptides and proteins. Here, we report the crystal struc-
tures of human testis ACE (tACE) and a homologue of ACE, known as
AnCE, from Drosophila melanogaster in complex with the most promising
selenium analogue of captopril (SeCap) determined at 2.4 and 2.35 A ˚ reso-
lution, respectively. The inhibitor binds at the active site of tACE and
AnCE in an analogous fashion to that observed for captopril and provide
the ﬁrst examples of a protein–selenolate interaction. These new structures
of tACE–SeCap and AnCE–SeCap inhibitor complexes presented here pro-
vide important information for further exploration of zinc coordinating
selenium-based ACE inhibitor pharmacophores with signiﬁcant antioxidant
activity.
Database
Structural data for the two SeCap complexes with ACE and AnCE have been deposited with
the RCSB Protein Data Bank under the codes 2YDM and 3ZQZ, respectively.
Introduction
Human angiotensin I-converting enzyme (ACE;
EC 3.4.15.1) is a zinc metallopeptidase that plays a
critical role in blood pressure regulation [1–7] by catal-
ysing the proteolysis of angiotensin I to the vasopres-
sor angiotensin II [8–10]. There are two isoforms of
human ACE: in somatic tissues, it exists as a glycopro-
tein composed of a mature single polypeptide chain of
1277 amino acids with two active centres, one in each
of the N- and C-domains [11]. Testis ACE (tACE) is
identical to the C-terminal half of somatic ACE,
except for a unique 36-residue sequence at its N-termi-
nus [12]. Both domains are heavily glycosylated (the
N-domain has 10 and the C-domain has 7 N-linked
glycosylation sites), cleave angiotensin I, are dependent
on chloride ion activation and share  55% amino
acid sequence identity.
Abbreviations
ACE, angiotensin I-converting enzyme; SeCap, selenium analogue of captopril; tACE, testis angiotensin I-converting enzyme.
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for the treatment of hypertension, heart failure, myo-
cardial infarction and diabetic nephropathy. In addi-
tion, a number of studies have suggested that
hypertension and oxidative stress are interdependent
[13,14]. Therefore, ACE inhibitors having antioxidant
properties are considered beneﬁcial for the treatment
of hypertension. Because selenium compounds are
known to exhibit better antioxidant behaviour than
their sulfur analogues [15,16], we have recently
reported the synthesis, characterization and antioxi-
dant activity of a number of selenium analogues of the
clinically used ACE inhibitor captopril [17,18]. It was
shown that selenium analogues of captopril (SeCap)
not only inhibit ACE activity, but also can effectively
scavenge peroxynitrite, a strong oxidant found in vivo
[19].
The two ACE homologues, AnCE and ACER, from
a nonvertebrate, Drosophila melanogaster, have been
studied in detail. AnCE is a single-domain protein,
reported to have biochemical resemblance to C-domain
ACE [20]. In addition the 3D structure(s) of native
AnCE and AnCE in complex with ACE inhibitors has
ﬁrmly established the high degree of conservation in
the active site of ACE [21,22].
Here, we report for the ﬁrst time, structural details
on the binding of one of the potent SeCaps (Fig. 1) to
tACE and AnCE, as elucidated by X-ray crystallogra-
phy at 2.4 and 2.35 A ˚ resolution, respectively. Using
these structures, we have been able to make a direct
comparison of the previously determined structures of
native tACE [23] and AnCE [22] with their respective
complex with captopril [22,24]. These structures are
useful in understanding a selenolate ligand’s coordina-
tion of zinc and its binding mode at the active site of
ACE and its homologue AnCE.
Results and Discussion
tACE–SeCap complex
The ﬁnal structure contains a zinc ion, one SeCap
inhibitor molecule, N-glycosylated carbohydrates at
two potential binding sites (Asn72, Asn109) and 54
water molecules (Table 1). No noticeable conforma-
tional change in the protein is observed upon inhibitor
binding. The topological arrangement of the ﬁnal
structure (Fig. 2A) is consistent with previously deter-
mined structures of tACE [23], as well as tACE in
complex with captopril [24]. One bound SeCap mole-
cule was unambiguously ﬁtted in the catalytic site of
tACE (Fig. 3A) with the aid of a clearly observed elec-
tron-density map.
The inhibitor SeCap molecule makes a direct inter-
action with the catalytic Zn
2+ ion (distance 2.5 A ˚ ,
Table 2) deep inside the active site channel (Fig. 2A),
similar to the zinc coordination in tACE–captopril
[24]. This interaction results in the formation of a
zinc–selenolate complex. The inhibitor is anchored
through the central carbonyl group and the proline
carboxylate group. The proline residue of SeCap inter-
acts with the S2¢ subsite of the active site via two
strong hydrogen bonds from two histidines (His513,
3.1 A ˚ ; His353, 2.6 A ˚ ). One oxygen atom of the proline
carboxylate group is held by interactions with Tyr520
(2.7 A ˚ ), Gln281 (2.7 A ˚ ) and Lys511 (3.0 A ˚ ) (Fig. 3A,
Table 2). In addition, it is held by seven hydrogen
bonds including two mediated through water mole-
cules, as calculated by HBPLUS [25] (Table 2). Thus,
the interactions of SeCap with tACE residues are
almost identical to those observed with captopril [24]
(Fig. 3B), which is not too surprising considering the
similarity between the two chemical structures
(Fig. 1).
AnCE–SeCap complex
The ﬁnal structure contains a zinc ion, one inhibitor
molecule, N-glycosylated carbohydrates at three poten-
tial binding sites (Asn53, Asn196, Asn311) and 201
water molecules (Table 1). No noticeable conforma-
tional change is observed upon inhibitor binding. The
topological arrangement of the ﬁnal structure (Fig. 2B)
is consistent with previously determined structures of
AnCE and AnCE in complex with captopril [21,22].
One bound SeCap molecule was unambiguously ﬁtted
in the catalytic site of AnCE (Fig. 4A) with the aid of
a clearly observed electron-density map.
The inhibitor SeCap molecule makes a direct inter-
action with the catalytic Zn
2+ ion, displacing the
water that is bound in the native enzyme (distance
2.7 A ˚ , Table 3) (Fig. 4A), similar to the zinc coordina-
tion in AnCE–captopril [21,22]. This interaction results
in the formation of a zinc–selenolate complex. The
carboxy-end of the proline moiety and the central car-
bonyl interact with the extended S1¢S2¢-binding site Fig. 1. Chemical structures of captopril and SeCap.
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of SeCap makes important contacts with the S2¢ sub-
site via two strong hydrogen bonds from two histidines
(His497, 3.1 A ˚ ; His337, 2.5 A ˚ ). One oxygen atom of
the proline carboxylate group interacts with Tyr504
(2.5 A ˚ ), Gln265 (2.9 A ˚ ) and Lys495 (2.9 A ˚ ) through
Table 1. X-ray diffraction data collection and reﬁnement statistics. Values in parentheses are for last resolution shell. SeCap, selenium ana-
logue of captopril; tACE, testis angiotensin I converting enzyme.
tACE–SeCap inhibitor complex AnCE–SeCap inhibitor complex
Resolution (A ˚) 2.4 2.35
Space group P212121
(one molecule⁄asymmetric unit)
R3
(one molecule⁄asymmetric unit)
Cell dimension (A ˚, deg) a = 56.1, b = 84.5, c = 132.3
a = b = c =9 0
a = 173.8, b = 173.8, c = 100.8
a = b = 90, c = 120
Total no. of observations 117329 179815
No. of unique reﬂections 23627 44663
Completeness (%) 97.4 (83.6) 94.7 (72.1)
I⁄r(I) 12.3 (2.2) 11.5 (1.6)
Rsymm
a 0.09 (0.62) 0.075 (0.53)
Rcryst
b⁄Rfree
c 0.21⁄0.26 0.20⁄0.24
No. of protein atoms 4687 4866
No. of solvent atoms 54 201
No. of inhibitor atoms 14 14
Deviation from ideality
Bond lengths (A ˚) 0.01 0.01
Bond angles (deg) 1.42 0.88
B-factor analysis
Protein all atoms 32.6 35.3
Protein main chain 32.2 35.2
Protein side chain 33.0 35.3
Solvent atoms 32.3 35.4
Inhibitor atoms 46.9 51.0
Zn
2+⁄Cl
) ions (tACE); Zn
2+ ion (AnCE) 35.7⁄44.0 33.9
Glycosylated sugars 52.7 54.0
a Rsymm = RhRi[|Ii(h) ) <I(h)>|⁄RhRi Ii(h)], where Ii is the ith measurement and <I(h)> is the weighted mean of all the measurements of I(h).
b Rcryst = Rh|Fo ) Fc|⁄RhFo, where Fo and Fc are observed and calculated structure factor amplitudes of reﬂection h, respectively.
c Rfree is
equal to Rcryst for a randomly selected 5% subset of reﬂections.
Fig. 2. (A) Structure of tACE (cyan) with inhibitor SeCap bound at the active site cavity (shown in spheres). The zinc ion (green sphere)
bound in the active site and N-glycosylated sugars (brown sticks) at potential sites, Asn72, Asn109 are shown. Protein termini are labelled.
(B) Structure of AnCE (blue) with inhibitor SeCap bound at the active site cavity (shown in spheres). The zinc ion (green sphere) bound in
the active site and N-glycosylated sugars (brown sticks) at potential sites, Asn53, Asn196, Asn311 are shown.
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tral carbonyl of SeCap is held by His337 and His497.
In addition, it is held by seven hydrogen bonds,
including two hydrogen bonds mediated through water
molecules, as calculated by HBPLUS [25] (Table 3).
Thus, the interactions of SeCap with AnCE residues
are almost identical to those observed with captopril
[21,22] (Fig. 4B).
Conclusions
There has been considerable interest in applications of
selenolate compounds because of their broad therapeu-
tic spectrum and low toxicity. The organoselenium
compound ebselen [2-phenyl-1,2-benzisoselenazol-
3(2H)-one] an anti-inﬂammatory and general antioxidant,
is also a potent inhibitor of extracellular nucleo-
side diphosphokinase [26]. Furthermore, Achillion
Pharmaceuticals (New Haven, CT, USA) has recently
developed a selenophene inhibitor of bacterial topoi-
somerases that shows promise as an antibiotic [27].
However, selenolates have not been exploited as metal-
loprotease inhibitors despite their antioxidant- and per-
oxynitrite-scavenging activities. This study has, for the
ﬁrst time, provided molecular details on the binding
and coordination of a selenium analogue of the potent
ACE inhibitor captopril with ACE and its homologue
AnCE. Captopril is one of the smallest ACE inhibitors
and with both ACE and AnCE, key interactions of the
selenium analogue’s central carbonyl and proline
carboxylate anchor the inhibitor in the cavernous
Fig. 3. (A) A stereo representation of tACE active site with bound inhibitor. The inhibitor molecule is shown in a stick model (brown) with
the electron density map contoured at 1r level. The zinc ion is shown as a green sphere and water molecules in light blue colour. Interacting
residues are labeled and atoms are coloured as follows: red for oxygen, blue for nitrogen and purple for selenium. Hydrogen bonds are
shown as dotted lines. (B) Comparison of SeCap (this study, left) and captopril (yellow sticks) binding [24] to tACE (right).
Table 2. Hydrogen bond contacts of testis angiotensin I converting
enzyme (tACE) with the selenium analogue of captopril (SeCap)
inhibitor.
Atom
Inhibitor
atom
Distance
(A ˚)
tACE Residue
His353 NE2 O1 2.6
His513 NE2 O1 3.1
Gln281 NE2 O2 2.7
Lys511 NZ O2 3.0
Tyr520 OH O2 2.7
Zinc ion
Zn Se 2.5
Water molecule
O O3 3.0
O Se 3.4
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space surrounding the P2¢ proline of SeCap is further
illustrated by the accommodation of silylated captopril
analogues in the active site of ACE [28]. Selenolates
are stronger zinc-binding groups than thiols, yet sur-
prisingly the IC50 value of SeCap was greater than that
of captopril [19]. This anomaly could be due to the
cooperativity of the two-domain somatic ACE and the
modest N-domain selectivity of captopril. Structures of
SeCap complex with the N-domain and somatic ACE
will undoubtedly shed further light on the binding of
this new zinc-binding group of compounds with ACE
and aid in the design of further selenium-based ACE
inhibitors.
Experimental procedures
tACE–SeCap complex
A variant of tACE (tACED36-g13, underglycosylated pro-
tein) was puriﬁed to homogeneity from Chinese hamster
ovary cells [29]. The inhibitor SeCap (Fig. 1, IC50 value of
36.4 ± 1.5 nM) was synthesized as reported recently [19].
A stock solution (5 mM) of SeCap was prepared by dissolv-
ing the inhibitor in deoxygenated water containing 10 mM
dithiothreitol. The crystals of the tACE complex with
SeCap were grown at 16  C using the hanging drop vapour
diffusion method. tACE protein (11.5 mgÆmL
)1 in 50 mM
Hepes, pH 7.5) was preincubated with SeCap (1 mM) on ice
for 3 h before crystallization. Preincubated sample (2 lL)
was mixed with the reservoir solution consisting of 13.5%
poly(ethylene glycol) 4000, 50 mM sodium acetate, pH 4.7
and 10 lM ZnSO4, and suspended above the well. Diffrac-
tion quality of cocrystals appeared after  10 days.
Fig. 4. (A) A stereo representation of AnCE active site with bound inhibitor. The inhibitor molecule is shown in a stick model (brown) with
the electron density map contoured at 1r level. The zinc ion is shown as a green sphere and water molecules in light blue colour. Interacting
residues are labeled and atoms are coloured as follows: red for oxygen, blue for nitrogen and purple for selenium. Hydrogen bonds are
shown as dotted lines. (B) Comparison of SeCap (this study, left) and captopril (yellow sticks) binding [22] to AnCE (right).
Table 3. Hydrogen bond contacts of AnCE with the selenium ana-
logue of captopril (SeCap) inhibitor.
Atom
Inhibitor
atom
Distance
(A ˚)
AnCE residue
Gln265 NE2 O2 2.9
His337 NE2 O1 2.5
Lys495 NZ O2 2.9
His497 NE2 O1 3.1
Tyr504 OH O2 2.5
Zinc ion
Zn Se 2.7
Water molecule
O O3 2.9
O O3 3.5
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were collected on the PX station IO2 at Diamond Light
Source (Didcot, UK). A total of 150 images were collected
using a Quantum-4 CCD detector (ADSC Systems,
Poway, CA, USA). No cryoprotectant was used to keep
the crystal at constant temperature (100 K) under the
liquid nitrogen jet during data collection. Raw data
images were indexed and scaled with XDS [30] and the
CCP4 program SCALA [31]. Initial phasing for structure
solution was obtained using the molecular replacement
routines of the program PHASER [32]. The atomic coordi-
nates of native tACE [23] (PDB code 1O8A) were used as
a search model. The resultant model was reﬁned using
REFMAC5 [33] and adjustment of the model was carried
out using COOT [34]. Water molecules were added at posi-
tions where Fo ) Fc electron-density peaks exceeded 3r
and potential H-bonds could be made. Based on electron-
density interpretation, the inhibitor and sugar moieties
were added in the complex structure and further reﬁne-
ment was carried out. The coordinate and parameter ﬁles
for SeCap were generated using SKETCHER [31]. Validation
was conducted with the aid of MOLPROBITY [35]. Figures
were drawn with PYMOL (DeLano Scientiﬁc, San Carlos,
CA, USA). Hydrogen bonds were veriﬁed with the pro-
gram HBPLUS [25]. The detailed reﬁnement statistics for
the complex structure are given in Table 1.
AnCE–SeCap complex
AnCE was cloned and expressed in Pichia pastoris as
described previously [22]. In brief, AnCE was puriﬁed to
homogeneity from culture media using hydrophobic inter-
action chromatography and size-exclusion chromatography.
The crystals of the AnCE complex with SeCap were grown
at 21  C by the hanging drop vapour diffusion method.
AnCE protein (10 mgÆmL
)1 in 50 mM Hepes, pH 7.5) was
preincubated with SeCap (1 mM) and 10 lM zinc acetate,
on ice for 3 h before crystallization. Preincubated sample
(2 lL) was mixed with the reservoir solution consisting of
1.3 M sodium citrate, 100 mM Hepes, pH 7.5 and suspended
above the well. Diffraction quality of cocrystals appeared
after  1 week. X-ray diffraction data for the AnCE–Se-
Cap complex were collected on the PX station I24 at Dia-
mond Light Source. A total of 170 images were collected
using a PILATUS 6M detector (Dectris, Baden, Switzer-
land). No cryoprotectant was used. Raw data images were
indexed and scaled with XDS [30] and the CCP4 program
SCALA [31]. Initial phasing for structure solution was
obtained using the molecular replacement routines of the
program PHASER [32]. The atomic coordinates of native
AnCE [22] (PDB code 2X8Y) were used as a search model.
The resultant model was reﬁned using REFMAC5 [33] and
adjustment of the model was carried out using COOT [34].
Water molecules were added at positions where Fo ) Fc
electron-density peaks exceeded 3r and potential H-bonds
could be made. Based on electron-density interpretation,
the inhibitor and sugar moieties were added in the complex
structure and further reﬁnement was carried out. The coor-
dinate and parameter ﬁles for SeCap were generated using
SKETCHER [31]. Validation was conducted with the aid of
MOLPROBITY [35]. Figures were drawn with PYMOL. Hydro-
gen bonds were veriﬁed with the program HBPLUS [25]. The
detailed reﬁnement statistics for the complex structure are
given in Table 1.
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